Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

This page is alzhub.org's plain-English summary of a published study, not the paper itself. It is generated from the record we hold for this study, sourced and linked below — check the original for the full text and methods.

✓ Peer-reviewed alzhub usefulness score 36 out of 100. Down syndrome and Alzheimer's

Topic: Brain proteins, microglia and lab models

Plain-language summary

Abstract Background To date, limited evidence exists on the different sensitivity of MRI versus [ 18 F]FDG‐PET to detect early cerebral changes along the Alzheimer's disease (AD) continuum in Down syndrome (DS). Therefore, we aimed to characterize volume and metabolism alterations in adults with DS and compare their performance in detecting AD clinical stages. Method Cross‐sectional study, including 92 adults with DS from the Down‐Alzheimer Barcelona Neuroimaging Initiative (34 asymptomatic without amyloid pathology [aDS A−], 20 asymptomatic with amyloid pathology [aDS A+], 12 with prodromal AD [pDS], and 26 with AD dementia [dDS]; Table 1), who underwent 3T‐MRI and [ 18 F]FDG‐PET. Amyloid status in the aDS group was determined using amyloid‐PET (>20 centiloids, n = 29) or CSF Aβ42/Aβ40 ratio (<0.062, Lumipulse, n = 25). Brain volume and metabolism values were extracted using the Hammers atlas, normalizing MRI volumes by total intracranial volume and PET images using the pons as reference region. We calculated standardized‐β coefficients, adjusted for sex and scanner, to assess the effectiveness of MRI and PET scans in identifying stages of AD (aDS A− vs. aDS A+; aDS vs. symptomatic DS [sDS=pDS + dDS]). Result Progressive brain volume loss and metabolic decline were observed along the AD continuum in DS. Compared to aDS A−, aDS A+ exhibited lower volume in multiple regions, particularly in the frontal lobe. sDS individuals showed widespread atrophy, predominantly in temporal areas (Figure 1). In contrast, no significant hypometabolism was detected in aDS A+ compared to aDS A−, but sDS individuals exhibited global hypometabolism, primarily in temporo‐parietal regions (Figure 2). Conclusion Amyloid pathology in aDS individuals is linked to frontal‐predominant atrophy without clear hypometabolism. In symptomatic stages, both MRI and [ 18 F]FDG‐PET revealed widespread involvement, with atrophy predominating in temporal regions and hypometabolism in temporo‐parietal areas. Unlike in sporadic AD, no brain region showed greater hypometabolism than atrophy, suggesting alternative contributing factors in the general population. Our findings also suggest that MRI outperforms [ 18 F]FDG‐PET in identifying brain changes associated with AD clinical stages in DS, which has implications for early diagnosis and clinical trials.

What this study adds

Evidence grade: Low

The record lists 29 participants. This cross-sectional imaging study found progressive brain volume loss and metabolic decline along the Alzheimer's continuum in adults with Down syndrome. It compares how well MRI and FDG-PET detect disease stages but does not test any treatment, cure or prevention.

Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.

Cite this study APA, Vancouver, BibTeX · download .bib or .ris

APA 7th

Arriola‐Infante, J. E., Morcillo-Nieto, A. O., Franquesa‐Mullerat, M., Zsadanyi, S. E., Vaqué‐Alcázar, L., Aranha, M. R., et al. (2025). Distinct Sensitivity of MRI Versus [ 18 F]FDG‐PET To Detect Cerebral Changes Across the Alzheimer's Continuum in Down Syndrome: A Multimodal Imaging Study. Alzheimer s & Dementia. https://doi.org/10.1002/alz70856_107114

Vancouver

Arriola‐Infante JE, Morcillo-Nieto AO, Franquesa‐Mullerat M, Zsadanyi SE, Vaqué‐Alcázar L, Aranha MR, et al. Distinct Sensitivity of MRI Versus [ 18 F]FDG‐PET To Detect Cerebral Changes Across the Alzheimer's Continuum in Down Syndrome: A Multimodal Imaging Study. Alzheimer s & Dementia. 2025. doi:10.1002/alz70856_107114.

BibTeX

@article{arriolainfante2025-294a9f95,
  author  = {Arriola‐Infante, José Enrique and Morcillo-Nieto, Alejandra Omaira and Franquesa‐Mullerat, María and Zsadanyi, Sára E. and Vaqué‐Alcázar, Lídia and Aranha, Mateus Rozalem and Parra, Jose Allende and Zhao, Zili and others},
  title   = {{Distinct Sensitivity of MRI Versus [ 18 F]FDG‐PET To Detect Cerebral Changes Across the Alzheimer's Continuum in Down Syndrome: A Multimodal Imaging Study}},
  journal = {Alzheimer s \& Dementia},
  year    = {2025},
  doi     = {10.1002/alz70856_107114},
  url     = {https://doi.org/10.1002/alz70856_107114}
}

Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record's author list ends in “et al.”, so not every author is named. Check the citation against the original before you use it.

Key findings

Why it matters

This cross-sectional imaging study found progressive brain volume loss and metabolic decline along the Alzheimer's continuum in adults with Down syndrome. It compares how well MRI and FDG-PET detect disease stages but does not test any treatment, cure or prevention.

Study details

How this study scored 36/100
How this study's score is builtJournal tier 7 of 10; Journal's citation record 2 of 4; Study design 0 of 12; Strength of evidence 1 of 5; Peer-review validation 10 of 10; How recent 4 of 5; Sample size 1 of 4; Effect reported 0 of 3; Studied in people 3 of 3; Randomized / blinded 0 of 2; Times cited 0 of 7; Citations per year 0 of 5; Impact for its field and year 0 of 6; Cited by studies here 0 of 6; Still being cited 0 of 4; Senior author's track record 2 of 4; Institution's track record 1 of 3; Multicenter collaboration 2 of 3; Indexed in PubMed 1 of 2; Free to read 2 of 2. Total 36 of 100.36 of 100 points earned64 not earned

Published in a peer-reviewed journal. Scored zero for study design, effect reported and randomized / blinded because the record does not state it.

ComponentPointsWhy
Journal tier 7 / 10 Tier 3 — peer-reviewed journal (Alzheimer s & Dementia)
Journal's citation record 2 / 4 Alzheimer s & Dementia: journal h-index 228 (OpenAlex, 2026-10-29)
Study design 0 / 12 No study design recorded — scores zero, not guessed (not stated in the record — scored 0)
Strength of evidence 1 / 5 Rated “low” in our summary
Peer-review validation 10 / 10 Peer-reviewed. Published as an article in a named peer-reviewed journal.
How recent 4 / 5 2025 — within 3 year(s) of the newest study here
Sample size 1 / 4 29 participants
Effect reported 0 / 3 No effect size reported — scores zero (not stated in the record — scored 0)
Studied in people 3 / 3 Studied in people (participant count stated)
Randomized / blinded 0 / 2 No randomization or blinding stated — scores zero (not stated in the record — scored 0)
Times cited 0 / 7 Cited 0 times (OpenAlex, 2026-10-10)
Citations per year 0 / 5 0.0 citations a year over 3 year(s) since 2025
Impact for its field and year 0 / 6 Cited 0.0× the average for papers of its field and year (OpenAlex FWCI)
Cited by studies here 0 / 6 No other study in this library cites it
Still being cited 0 / 4 Cited 0 times in 2024–2026 (2026 still in progress; OpenAlex)
Senior author's track record 2 / 4 Last-listed author Alexandre Bejanin: h-index 36 (OpenAlex, whole career)
Institution's track record 1 / 3 Universitat de Barcelona: institution h-index 1,049 (OpenAlex)
Multicenter collaboration 2 / 3 OpenAlex lists 6 institution(s) in 1 country
Indexed in PubMed 1 / 2 Not in PubMed, but has a DOI
Free to read 2 / 2 Free to read
Total 36 / 100 —

What each of these 20 components measures, and what this score is not →

Read the original

Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).

Studies in the library that share something with this one. The line above each title says what.

Related studies in Down syndrome and Alzheimer's from nearby years

Also tagged “down”

527 studies in the library carry the topic tag “down”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 527 tagged studies.

Studies sharing this one's topic tags

Similar studies

More on Down syndrome and Alzheimer's

See all studies in Down syndrome and Alzheimer's →